Prostate cancer heterogeneity: Discovering novel molecular targets for therapy
- PMID: 28231559
- DOI: 10.1016/j.ctrv.2017.02.001
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy
Abstract
Prostate cancer (PCa) shows a broad spectrum of biological and clinical behavior, which represents the epiphenomenon of an extreme genetic heterogeneity. Recent genomic profiling studies have deeply improved the knowledge of the genomic landscape of localized and metastatic PCa. The AR and PI3K/Akt/mTOR signaling pathways are the two most frequently altered, representing therefore interestingly targets for therapy. Moreover, somatic or germline aberrations of DNA repair genes (DRGs) have been observed at high frequency, supporting the potential role of platinum derivatives and PARP inhibitors as effective therapeutic strategies. In the future, the identification of driver mutations present at a specific stage of the disease, the classification PCa based on specific molecular alterations, and the selection of the most appropriate therapy based on biomarkers predictors of response represent the foundations for an increasingly more accurate personalized medicine.
Keywords: BRCA; CRPC; DRG; Heterogeneity; PARPi; PTEN; Prostate cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.Int J Mol Sci. 2021 Oct 14;22(20):11088. doi: 10.3390/ijms222011088. Int J Mol Sci. 2021. PMID: 34681745 Free PMC article. Review.
-
The molecular underpinnings of prostate cancer: impacts on management and pathology practice.J Pathol. 2017 Jan;241(2):173-182. doi: 10.1002/path.4826. Epub 2016 Dec 1. J Pathol. 2017. PMID: 27753448 Review.
-
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?Biochim Biophys Acta Mol Cell Res. 2020 Sep;1867(9):118731. doi: 10.1016/j.bbamcr.2020.118731. Epub 2020 Apr 29. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 32360668 Review.
-
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.Cell Oncol. 2010;32(1-2):11-27. doi: 10.3233/CLO-2009-0487. Cell Oncol. 2010. PMID: 20203370 Free PMC article.
-
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.Int J Mol Sci. 2023 Jan 24;24(3):2289. doi: 10.3390/ijms24032289. Int J Mol Sci. 2023. PMID: 36768610 Free PMC article. Review.
Cited by
-
Exploiting Epigenetic Alterations in Prostate Cancer.Int J Mol Sci. 2017 May 9;18(5):1017. doi: 10.3390/ijms18051017. Int J Mol Sci. 2017. PMID: 28486411 Free PMC article. Review.
-
TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation.Int J Biochem Cell Biol. 2021 Jan;130:105885. doi: 10.1016/j.biocel.2020.105885. Epub 2020 Nov 20. Int J Biochem Cell Biol. 2021. PMID: 33227392 Free PMC article.
-
HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.Cells. 2018 Sep 1;7(9):129. doi: 10.3390/cells7090129. Cells. 2018. PMID: 30200497 Free PMC article.
-
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7. Nat Commun. 2019. PMID: 31748536 Free PMC article.
-
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.Med Res Rev. 2019 May;39(3):910-960. doi: 10.1002/med.21548. Epub 2018 Nov 22. Med Res Rev. 2019. PMID: 30565725 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
